PLAA antibody (AA 101-200)
-
- Target See all PLAA Antibodies
- PLAA (Phospholipase A2-Activating Protein (PLAA))
-
Binding Specificity
- AA 101-200
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This PLAA antibody is un-conjugated
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- Predicted Reactivity
- Human,Mouse,Rat,Dog,Cow,Pig,Horse,Rabbit
- Purification
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human Phospholipase A2 activator protein
- Isotype
- IgG
- Top Product
- Discover our top product PLAA Primary Antibody
-
-
- Application Notes
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- Expiry Date
- 12 months
-
-
Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients." in: Atherosclerosis, Vol. 230, Issue 1, pp. 164-70, (2013) (PubMed).
: "
-
Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients." in: Atherosclerosis, Vol. 230, Issue 1, pp. 164-70, (2013) (PubMed).
-
- Target
- PLAA (Phospholipase A2-Activating Protein (PLAA))
- Alternative Name
- PLAA/Phospholipase A2 activator protein (PLAA Products)
- Synonyms
- cb623 antibody, zgc:56568 antibody, zgc:66193 antibody, wu:fc45d08 antibody, wu:fi33e06 antibody, PLAA antibody, doa1 antibody, pla2p antibody, plap antibody, DOA1 antibody, PLA2P antibody, PLAP antibody, 2410007N06 antibody, AI536418 antibody, AU018445 antibody, AW208417 antibody, D4Ertd618e antibody, Ufd3 antibody, Plap antibody, phospholipase A2-activating protein antibody, phospholipase A2 activating protein antibody, phospholipase A2-activating protein L homeolog antibody, phospholipase A2-activating protein S homeolog antibody, phospholipase A2, activating protein antibody, plaa antibody, PLAA antibody, plaa.L antibody, plaa.S antibody, Plaa antibody
- Background
-
Synonyms: DOA1, PLAP, PLA2P, Phospholipase A-2-activating protein, PLAA
Background: Phospholipase A2 activator protein (PLAP), activates PLA2 (phospholipase A2 enzyme) and is an important mediator of eicosanoid generation. Also known as a pro-inflammatory agent, PLAP has been found in inflamed tissues and synovial fluid from patients with rheumatoid arthritis. As such, it is believed to play an important role in the regulation of inflammatory diseases. The formation of PLAP can be stimulated by IL-1 beta and TNF-alpha.
- Gene ID
- 9373
- UniProt
- Q9Y263
-